Ibrutinib in mantle cell lymphoma patients: glass half full? Evidence and opinion.
Ontology highlight
ABSTRACT: Mantle cell lymphoma (MCL) is a rare subtype of non-Hodgkin's lymphoma typically marked by an aggressive clinical course and a predilection for relapse. The B-cell receptor (BCR) signaling survival pathway is chronically activated in MCL, contributing to its pathogenesis. Ibrutinib is an inhibitor of Bruton's tyrosine kinase, a vital component of this pathway. This article details the current clinical experience with ibrutinib in the treatment of patients with MCL, including completed and published clinical trials and reviews potential adverse events (AEs) and pitfalls associated with ibrutinib therapy. Although most AEs experienced by patients treated with ibrutinib are mild, some can be severe and treatment limiting and may be attributed to off-target effects. Ibrutinib is a very promisi
SUBMITTER: Stephens DM
PROVIDER: S-EPMC4556969 | biostudies-literature | 2015 Oct
REPOSITORIES: biostudies-literature
ACCESS DATA